Last Updated: November 16, 2026

Details for Patent: 10,888,516

« Back to Dashboard


Summary for Patent: 10,888,516
Title:Soluble estradiol capsule for vaginal insertion
Abstract:According to various embodiments of this disclosure, pharmaceutical formulations comprising solubilized estradiol are provided. In various embodiments, such formulations are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.
Inventor(s):Brian A. Bernick, Julia M. Amadio, Peter H. R. Persicaner, Thorsteinn Thorsteinsson, Janice Louise Cacace, Frederick D. Sancilio, Neda Irani
Assignee: TherapeuticsMD Inc
Application Number:US16/833,213
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,888,516
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;
Patent landscape, scope, and claims:

Scope and Claims Analysis of US Drug Patent 10,888,516: Estradiol-Containing Intravaginal Soft Gel Capsules for Vulvovaginal Atrophy

US Patent 10,888,516 is claim-scoped tightly around a specific drug product architecture and exposure target for intravaginal estradiol dosing for vulvovaginal atrophy (VVA). The independent claim (claim 1) is anchored to (i) an intravaginal soft gelatin capsule with a gelatin shell and a defined “fatty ester” fill, (ii) a dosing regimen (14 days once daily then twice weekly), and (iii) a pharmacokinetic exposure window (estradiol AUC and Cmax each 80% to 125% vs a specifically identified “reference” soft gelatin capsule). Dependent claims then narrow further to particular surfactants (including HLB-defined nonionic surfactants), capsule disintegration behavior, capsule geometry and dimensions, gelatin shell composition (including 150 bloom Type B gelatin with hydrolyzed collagen and glycerin plus optional plasticizer), and specific fill mass/viscosity/mass and “ratio” structures.

What is the core claim scope of US 10,888,516?

What does claim 1 require, in operational terms?

Claim 1 requires all of the following elements to be present:

  1. Indication and patient population

    • Method of treating a symptom of vulvovaginal atrophy in a female human in need thereof.
  2. Dosage form and route

    • Estradiol-containing soft gelatin capsule administered intravaginally.
    • Capsule comprises:
      • Gelatin shell surrounding
      • Estradiol-containing liquid fill material
  3. Dose strength range

    • The fill contains 1 to 10 mcg estradiol.
  4. Fill excipient class and viscosity window

    • The fill is made from one or more C6 to C14 fatty acid mono-, di-, or triesters of glycerol.
    • The fill has viscosity between 50 and 1000 cP at 25°C.
  5. Dosing regimen

    • Once daily for 14 days
    • Then one capsule twice weekly thereafter.
  6. PK “bioequivalence-like” exposure constraint tied to a reference product

    • Intravaginal administration must produce estradiol AUC and estradiol Cmax each 80% to 125% of those obtained with a reference soft gelatin capsule.
    • The reference soft gelatin capsule is defined as:
      • Soft gelatin shell + reference liquid fill
      • Reference fill includes:
        • ~270 mg C8 to C10 triglyceride composition with ≥80 wt% caprylic acid/capric acid mixture
        • ~30 mg surfactant comprising PEG-6 stearate, PEG-32 stearate, and ethylene glycol palmitostearate
        • 1 to 10 mcg estradiol
      • Reference fill viscosity also within 50 to 1000 cP at 25°C
    • The claim therefore ties infringement not just to formulation class and dose, but also to measured exposure outcomes versus a defined comparator.

Why the exposure window matters for infringement and validity

The PK constraint functions like a functional limitation. Even if a competitor uses the same broad excipient class (C6–C14 glycerol fatty esters) and the same regimen, the method may fall outside the claim if the competitor’s formulation does not achieve AUC and Cmax both within 80% to 125% of the reference product’s intravaginal PK.

In practice, that shifts design space and litigation posture toward:

  • comparative PK testing,
  • careful matching of fill composition/viscosity/vehicle behavior,
  • and evidentiary focus on AUC and Cmax obtained under comparable conditions.

What formulations are implicitly “safe harbors” or “tripwires”?

Primary tripwire: fatty ester class + viscosity

Claim 1 requires the fill to be C6–C14 glycerol fatty ester mono/di/tri-esters and to have viscosity 50–1000 cP at 25°C. That combination is a key formulation perimeter. If a competitor uses:

  • fatty ester chains outside C6–C14,
  • different backbone chemistry (e.g., non-glycerol esters or non-ester lipids),
  • or a viscosity outside 50–1000 cP at 25°C, the method claim’s first gate likely fails.

Secondary tripwire: PK window relative to a defined reference capsule

Even with in-range excipients and viscosity, infringement depends on achieving the PK window. The claim’s reference product is spelled out with specific lipid mass (~270 mg triglyceride with ≥80% caprylic/capric mixture) and specific surfactant package (~30 mg PEG-6 stearate + PEG-32 stearate + ethylene glycol palmitostearate).

That precision makes the reference comparator hard to “distance” without changing formulation behavior enough to alter AUC and/or Cmax.

How do dependent claims narrow product design?

Surfactant composition and HLB limitations (claims 2, 3, 10–12, 18)

  • Claim 2: fill further comprises a nonionic surfactant.
  • Claim 3 / claim 12: nonionic surfactant comprises PEG-6 stearate, PEG-32 stearate, and ethylene glycol palmitostearate.
  • Claims 10–11: nonionic surfactant has HLB ≤ ~10 or more specifically ~9 to ~10.
  • Claim 18: defines a 9:1 ratio of one or more C6–C14 glycerol fatty esters to nonionic surfactant.

These are meaningful infringement constraints because they require specific surfactant chemistry and balance. A product with different nonionic surfactant chemistry or surfactant ratio is more likely to fall outside dependent coverage even if claim 1’s broader requirements are otherwise met.

Clinical phenotype limitation (claim 4)

  • Claim 4: symptom is dyspareunia. This narrows the method-of-use to a specific VVA symptom. If litigation targets dyspareunia-related methods, claim 4 tightens the permissible clinical framing.

Disintegration behavior and capsule residue (claim 5)

  • Claim 5: each capsule disintegrates in the vagina leaving no capsule residue. This is a functional and performance limitation tied to in vivo disintegration. Competitors using formulations that leave residue (or different disintegration kinetics) are more likely to evade claim 5.

Capsule geometry and size (claims 6–9, 16–17)

Claims 6–9 and 16–17 define physical attributes.

  • Claim 6: capsule shape and size substantially similar to reference.
  • Claim 7: capsule shape and size identical to reference.
  • Claim 8: wider bottom portion, narrower top portion.
  • Claim 9: tear drop, cone with frustoconical end, or cylinder with wider cap portion.
  • Claim 16: maximal internal length ~0.69 inches between opposing interior wall points.
  • Claim 17: wall thickness perpendicular to interior/exterior surfaces ~0.108 inches.

Geometry-and-dimensions limitations are strong for infringement analysis against “look-alike” forms. A competitor could use similar lipids and PK profile yet still step outside these claims if dimensions and shape diverge.

Gelatin shell composition (claims 13–14)

  • Claim 13: gelatin shell comprises:
    • 150 bloom Type B gelatin
    • hydrolyzed collagen
    • glycerin
  • Claim 14: optional plasticizer: sorbitan-sorbitol based soft gel plasticizer.

These limitations are product-manufacturing-recipe constraints. A competitor can adjust shell composition while attempting to keep overall capsule performance and PK exposure, but it may exit coverage of these dependent claims.

Fill mass limitation (claim 15)

  • Claim 15: estradiol-containing fill material mass about 300 mg.

This could matter for competitors whose lipid loading and capsule capacity differ.

Reference PK “does not substantially raise” constraint (claim 19)

  • Claim 19: administering the reference soft gelatin capsule does not substantially raise circulating estradiol blood levels after administration.

This claim introduces a blood-level qualification. It also suggests the reference comparator is intended to function as a low systemic exposure product, consistent with intravaginal estradiol minimal systemic exposure design goals. Competitors must be careful in clinical framing and in evidence that blood levels are not substantially raised.

How does the patent landscape typically position around this claim type?

US 10,888,516’s structure indicates it is a formulation-and-regimen patent with PK/performance limitations. In the US, that claim style typically competes against:

  • earlier patents on intravaginal estradiol vehicles (soft gels, inserts, creams, tablets),
  • later patents on specific excipient packages, viscosity targets, dosing regimens, and capsule geometry,
  • and method-of-use patents keyed to specific symptoms such as dyspareunia.

Because claim 1 explicitly references a detailed “reference soft gelatin capsule,” the patent is likely prosecuting novelty over a particular product design and performance envelope. That reference product definition is a litigation and claim-construction anchor.

What are the practical infringement scenarios for competitors?

Scenario A: near-identical “soft gel” with matched PK

A generic-like intravaginal estradiol soft gel that:

  • uses C6–C14 glycerol fatty esters with viscosity 50–1000 cP,
  • delivers 1–10 mcg estradiol,
  • uses the same once-daily 14-day then twice-weekly regimen,
  • and achieves AUC and Cmax within 80%–125% of the reference comparator, is inside claim 1 irrespective of naming. Dependent claims add further narrowing based on surfactant package, disintegration behavior, geometry/dimensions, and shell recipe.

Scenario B: same regimen and capsule, different lipid chemistry

If a competitor substitutes triglycerides or esters outside the C6–C14 glycerol ester mono/di/triester class, claim 1 likely fails. If it retains the class but changes viscosity outside 50–1000 cP, claim 1 may fail as well.

Scenario C: same lipid class, different surfactant package

Changing surfactant chemistry may evade dependent claims (2–3, 10–12, 18) but can still leave exposure-limited claim 1 in play. The litigation focus shifts to whether AUC and Cmax remain within 80%–125% of the reference product.

Scenario D: different capsule geometry/dimensions

A competitor can attempt to avoid dependent coverage (claims 6–9, 16–17) by using a different shell geometry, dimensions, or tear-drop/cone/cylinder profile. Even if claim 1 is implicated, those dependent claims would be harder to reach.

Scenario E: disintegration differs (capsule residue)

If a product leaves residue or does not disintegrate as claimed, claim 5 becomes harder to satisfy. The independent claim may still be implicated depending on whether PK and compositional requirements are met.

What patent estate questions matter for Orange Book-style exclusivity and generic risk?

US 10,888,516 is a US patent with method claims, and its strength against generic entry depends on:

  • how many additional patents cover other aspects (shell, fill, process, method of use),
  • whether the method-of-use is listed for an FDA-approved product in relevant regulatory listings,
  • and whether competitors can redesign to change PK exposure outside the 80%–125% window.

Without the underlying Orange Book listing, FDA approval mapping, and the patent’s prosecution history, it is not possible to produce a reliable “who can launch when” schedule tied to exclusivity and listing status.

Key Takeaways

  • Claim 1 is not a generic “intravaginal estradiol soft gel” claim. It is limited by a specific combination of vehicle class (C6–C14 glycerol fatty mono/di/triesters), viscosity window (50–1000 cP at 25°C), dosing regimen (14 days once daily then twice weekly), dose range (1–10 mcg), and a PK exposure window (AUC and Cmax each 80%–125% of a defined reference product).
  • Dependent claims add further constraints around nonionic surfactant chemistry and HLB, surfactant ratio, dyspareunia symptom targeting, complete disintegration without residue, capsule geometry and exact internal dimensions, and detailed gelatin shell composition.
  • For generic or follow-on developers, the main design lever is to alter formulation behavior and measured PK so that AUC and/or Cmax fall outside the 80%–125% reference window, while also navigating dependent-claim barriers on surfactants, dimensions, and disintegration.

FAQs

1) Does US 10,888,516 require the exact reference capsule composition to infringe?
Claim 1 uses the reference capsule to set the PK target (80%–125% AUC and Cmax). The competitor’s formulation does not have to replicate the reference excipient masses to be analyzed against claim 1, but it must achieve the claimed exposure window relative to that reference.

2) Can a competitor avoid claim 5 by changing disintegration kinetics or leaving residue?
Yes. Claim 5 adds a performance limitation: capsules disintegrate in the vagina leaving no residue. If the competitor product leaves residue, it is likely out of claim 5.

3) Are surfactant HLB values a requirement or just guidance?
They are claim limitations in claims 10–11 when those dependent claims are asserted. HLB must be ≤ about 10 or about 9 to about 10 depending on the specific dependent claim theory.

4) How do capsule dimensions affect infringement strategy?
Dependent claims 16–17 impose specific internal length and thickness values. Changing capsule geometry and thickness can evade those dependent claims even if the independent claim is otherwise implicated.

5) What clinical symptom framing matters most under the patent?
Claim 4 narrows the method to dyspareunia. For method-of-use enforcement tied to symptom endpoints, dyspareunia-related labeling and clinical claims are the most relevant.

References

  1. United States Patent 10,888,516.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 10,888,516

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mayne Pharma IMVEXXY estradiol INSERT;VAGINAL 208564-001 May 29, 2018 AB RX Yes Yes 10,888,516 ⤷  Start Trial TREATMENT OF DYSPAREUNIA ⤷  Start Trial
Mayne Pharma IMVEXXY estradiol INSERT;VAGINAL 208564-001 May 29, 2018 AB RX Yes Yes 10,888,516 ⤷  Start Trial TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY ⤷  Start Trial
Mayne Pharma IMVEXXY estradiol INSERT;VAGINAL 208564-002 May 29, 2018 AB RX Yes Yes 10,888,516 ⤷  Start Trial TREATMENT OF DYSPAREUNIA ⤷  Start Trial
Mayne Pharma IMVEXXY estradiol INSERT;VAGINAL 208564-002 May 29, 2018 AB RX Yes Yes 10,888,516 ⤷  Start Trial TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,888,516

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2782584 ⤷  Start Trial 301153 Netherlands ⤷  Start Trial
European Patent Office 2782584 ⤷  Start Trial 2021C/558 Belgium ⤷  Start Trial
European Patent Office 2782584 ⤷  Start Trial 122021000080 Germany ⤷  Start Trial
European Patent Office 2782584 ⤷  Start Trial LUC00245 Luxembourg ⤷  Start Trial
European Patent Office 2782584 ⤷  Start Trial 132021000000197 Italy ⤷  Start Trial
European Patent Office 2782584 ⤷  Start Trial C202130068 Spain ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.